Heparin is a blood thinner or disaccharide anticoagulant which prevents the formation of blood clots and is produced in the body by mast cells and basophils. It is a naturally occurring anticoagulant released from mast cells. Heparin is also known as Unfractionated heparin (UH) is a heterogeneous preparation of anionic, sulfated glycosaminoglycan polymer. Its mechanism of action includes binding reversibly to antithrombin III (ATIII) and significantly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa.
MARKET DYNAMICS
The heparin market is anticipated to grow in the forecast, rising cases of conditions such as coronary heart disease, pulmonary embolism and deep vein thrombosis. Myocardial infarction (MI) is one of the major complications of coronary heart disease. In addition, increasing number of accidents and surgeries is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Heparin Market Analysis to 2028" is a specialized and in-depth study of the in pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of heparin market with detailed market segmentation by type, by route of administration, by application, end user and geography. The global heparin market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading heparin market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global heparin market is segmented on the basis of type, by route of administration, by application, end user. Based on type, market is segmented low molecular weight heparin, ultra-low molecular weight heparin and unfractionated heparin. The heparin market is categorized based on route of administration in Intravenous and Subcutaneous. By application the market is segmented into venous thromboembolism, atrial fibrillation, renal impairment, coronary artery disease and others. Based on end user hospitals, blood and stem cell banks, others
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global heparin market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The heparin market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting heparin market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the heparin market in these regions.
MARKET PLAYERS
The reports cover key developments in the heparin market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. Below mentioned is the list of few companies engaged in the heparin market.
The report also includes the profiles of key heparin market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- GlaxoSmithKline plc
- Pfizer, Inc.
- Baxter
- Leo Pharma A/S
- Sanofi
- Dr. Reddy's Laboratories Ltd.
- Aspen Holdings
- B. Braun Medical Inc.
- Fresenius SE & Co. KGaA
- EMD Millipore
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.